<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>1340984</identifier>
<setSpec>0034-9887</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Kramer, V</dc:author>
<dc:description xml:lang="en">Premarketing clinical studies of drugs have several limitations with respect to adverse reactions. Information obtained from postmarketing studies is important for determining drug safety. Drug surveillance has been developed to detect, evaluate and classify information related to adverse reactions to drugs. In this article different methods and strategies adopted in different countries for drug surveillance are described. Finally, the situation in Chile is analyzed and the need for a National Center of Drug Surveillance is stressed.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1992 Sep </dc:date>
<dc:title xml:lang="es">Farmacovigilancia.</dc:title>
<dc:title xml:lang="en">[Drug surveillance].</dc:title>
<dc:publisher>Revista medica de Chile</dc:publisher>
</metadata>
</record>
</pubmed-document>
